Madrigal Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Bill Sibold

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	7.8yrs

Recent management updates

Recent updates

CEO

Bill Sibold (57 yo)

less than a year

Tenure

Mr. William J. Sibold, also known as Bill, serves as Chief Executive Officer, President and Director at Madrigal Pharmaceuticals, Inc. since September 8, 2023. Mr. Sibold joined Madrigal Pharmaceuticals, I...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Rebecca Taub	Founder	12.7yrs	US$4.66m	2.06% $ 93.6m
Brian Lynch	Executive Officer	less than a year	US$4.76m	0.016% $ 711.2k
Alex Howarth	Executive Officer	less than a year	US$3.48m	0.013% $ 573.0k
William Sibold	CEO, President & Director	less than a year	no data	no data
Mardi Dier	CFO & Senior VP	less than a year	no data	no data
Ronald Filippo	Chief Information Officer	less than a year	no data	no data
Tina Ventura	Chief Investor Relations Officer	less than a year	no data	no data
Justin Drinkwine	VP, Senior Associate General Counsel & Assistant Secretary	no data	no data	no data
Clint Wallace	Chief Human Resources Officer	less than a year	no data	no data
Edward Chiang	Senior Vice President of Clinical & Technical Operations	no data	no data	no data
Thomas Hare	Senior Vice President of Clinical Management	no data	no data	no data
Robert Waltermire	Chief Pharmaceutical Development Officer	2.8yrs	no data	0.0041% $ 185.0k

0.3yrs

Average Tenure

59yo

Average Age

Experienced Management: YDO1's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Rebecca Taub	Founder	7.8yrs	US$4.66m	2.06% $ 93.6m
William Sibold	CEO, President & Director	less than a year	no data	no data
Frederick Craves	Independent Lead Director	7.8yrs	US$235.31k	2.21% $ 100.4m
Kenneth Bate	Independent Director	7.8yrs	US$248.43k	0.0056% $ 255.8k
Julian Baker	Independent Chairman of the Board	less than a year	no data	no data
Paul Friedman	Director	7.8yrs	US$5.40m	4.46% $ 202.5m
Richard Levy	Independent Director	7.8yrs	US$240.93k	0.043% $ 1.9m
James Daly	Independent Director	4.9yrs	US$235.31k	0.0056% $ 255.8k
Raymond Cheong	Independent Director	less than a year	no data	no data

7.8yrs

Average Tenure

65yo

Average Age

Experienced Board: YDO1's board of directors are considered experienced (7.8 years average tenure).

Madrigal Pharmaceuticals Management

Management criteria checks 1/4

Key information

Recent management updates

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Madrigal Pharmaceuticals, Inc. Announces Additions to its Leadership Team

Madrigal Pharmaceuticals, Inc. Appoints Ronald Filippo as Chief Information Officer

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

Recent updates

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Madrigal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. Announces FDA Approval of Rezdiffra™ (Resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (Nash) with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Forecast breakeven date moved forward to 2025

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Forecast breakeven date pushed back to 2026

New major risk - Financial position

New major risk - Share price stability

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Madrigal Pharmaceuticals, Inc. Announces Additions to its Leadership Team

New major risk - Share price stability

Madrigal Pharmaceuticals, Inc. Appoints Ronald Filippo as Chief Information Officer

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

New major risk - Financial position

Madrigal Pharmaceuticals, Inc. Announces the Resignation of Remy Sukhija as Chief Commercial Officer

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of Nash with Liver

Madrigal Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Madrigal Pharmaceuticals, Inc. Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Forecast to breakeven in 2025

Madrigal Pharmaceuticals, Inc. Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of Nash with Liver Fibrosis

Forecast to breakeven in 2025

Madrigal Pharmaceuticals, Inc. announced that it has received $90 million in funding

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

Insufficient new directors

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

Madrigal Pharmaceuticals, Inc. Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Madrigal Pharmaceuticals Provides Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

Madrigal Pharmaceuticals to Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom

Madrigal Pharmaceuticals, Inc. Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

Madrigal Pharmaceuticals, Inc. Offers Patients Resmetirom in Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study

Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom

Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial Maestro-Nafld-1

New 90-day low: €89.88

Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 Maestro NAFLD-1 Trial

New 90-day high: €112

New 90-day high: €107

Madrigal Pharmaceuticals Announces Acceptance of Three Abstracts by the Liver Meeting Digital Experience

New 90-day low - €83.24

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age